-
Sector Analysis
Chronic Kidney Disease: Epidemiology Report and Forecast to 2035
Why Does Chronic Kidney Disease Epidemiology Matter? Chronic kidney disease (CKD), also known as chronic renal disease, is characterized by a gradual loss of kidney function over time. As CKD progresses, the accumulation of fluid and waste in the body can worsen and eventually lead to kidney failure. The glomerular filtration rate (GFR) is a key measure of kidney function and is used in the diagnosis and classification of CKD. Across the seven major pharmaceutical markets (7MM), total prevalent cases...
-
Sector Analysis
Male Infertility Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
Report Value Proposition – Why Does the Male Infertility Therapeutics Market Matter? Male infertility remains an important yet underserved therapeutic area, with growing attention on improving diagnosis, understanding disease mechanisms, and developing targeted treatment options. Although diagnosed prevalence is expected to remain relatively stable across the seven major pharmaceutical markets (7MM), significant unmet clinical needs and limited approved therapies continue to create opportunities for innovation and investment. GlobalData's Male Infertility Therapeutics Market Analysis provides a comprehensive assessment of the market...
-
Product Insights
Clinical Trials: A Dive into Clinical Trial Sites
The clinical trials data used for these analyses was extracted from GlobalData’s Clinical Trials Database. The data included clinical trial sites used in clinical trials with a start date between January 1, 2020, and December 31, 2025, which were captured in the database as of April 21, 2026. The trial sites were analyzed and segmented by phase, status, sponsor type (industry versus non-industry), top sponsors, top CROs, geography, therapy area, and indication.
-
Sector Analysis
Slovakia's WTP Thresholds for Drug Reimbursement Evaluations - An Uncertain Future for Innovation
GlobalData takes a detailed look at the changing willingness-to-pay (WTP) thresholds for drug reimbursement evaluations in Slovakia, in the midst of regulatory uncertainty following the withdrawal of a proposed draft decree in May 2025, which would have drastically worsened the prospects for new innovative therapies in the country.
-
Sector Analysis
Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics. In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData’s epidemiology forecast. Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC. The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in...
-
Sector Analysis
The Keytruda Patent Cliff: Pricing Dynamics Following Biosimilar Competition
As a blockbuster therapy in immuno-oncology, Keytruda has undoubtedly established itself as one of the most clinical and commercially successful medicines across the global biopharmaceutical landscape. Its upcoming loss of exclusivity therefore represents one of the most consequential and prominent events in the global oncology market, with far-reaching pricing implications.
-
Sector Analysis
Disruptions to Vaccine Policy and the Future of mRNA Under the Second Trump Administration
US vaccine policy has experienced rapid changes since the start of the second Trump administration, raising concerns around future outbreaks of preventable infectious diseases, declining vaccination rates and the development of new vaccines.
-
Thematic Analysis
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
GLP 1RA therapies have shifted from treating T2D to becoming a multi indication therapy. GLP 1RAs were originally developed for type 2 diabetes (Byetta in 2005), and since 2014 they have expanded beyond T2D, starting with obesity (Saxenda) and then additional indications. GLP 1RA sales increased significantly from 2022 onwards, driven by newer therapies targeting obesity. This growth was driven by the entry and rapid uptake of Mounjaro and Wegovy (Mounjaro: ~$0.5B in 2022 to ~$23B in 2025; Wegovy: ~$0.9B...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, April 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights
Why Does ESCMID Global 2026 Matter for Your Business? ESCMID Global remains one of the most influential infectious diseases conferences for tracking emerging therapies, clinical data, and competitive developments across viral and fungal disease markets. This report provides a focused analysis of the key presentations, scientific sessions, and industry-sponsored symposia featured at ESCMID Global 2026, held in Munich, Germany between April 17 and 21. You can use this report to: Understand emerging trends in infectious disease therapeutics Analyze late-stage clinical...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.